

Title (en)
CELLULAR IMMUNOGENS USEFUL AS CANCER VACCINES

Title (de)
ZELLULÄRE IMMUNOGENE, DIE ALS IMPFSTOFFE GEGEN KREBS BRAUCHBAR SIND

Title (fr)
IMMUNOGENES CELLULAIRES UTILES EN TANT QUE VACCINS CONTRE LE CANCER

Publication
EP 0923284 A4 20030326 (EN)

Application
EP 97902934 A 19970113

Priority
• US 9700582 W 19970113
• US 1026296 P 19960119

Abstract (en)
[origin: WO9725860A1] A cellular immunogen is provided for immunizing a host against the effects of the product of a target proto-oncogene, where the overexpression of the target proto-oncogene is associated with a malignancy. The cellular immunogen comprises host cells which have been transfected with at least one transgene construct comprising a transgene cognate to the target proto-oncogene and a strong promoter to drive the expression of the transgene in the transfected cells. The transgene encodes a gene product which induces host immunoreactivity to host self-determinants of the product of the target proto-oncogene gene. The transgene may comprise, for example, wild-type or mutant retroviral oncogene DNA cognate to the target proto-oncogene; or wild-type or mutant proto-oncogene DNA of a species different from the host species. The cellular immunogen may be prepared from biopsied host cells, e.g. skin fibroblasts, which are stably or transiently transfected with the transgene construct containing the cognate transgene. The host cells transfected with the cognate transgene construct, are then returned to the body of the host to obtain expression of the cognate transgene in the host.

IPC 1-7
A01K 63/00; **A61K 39/00**; **A61K 39/38**; **A61K 48/00**; **C12N 5/00**; **C12N 15/00**

IPC 8 full level
C12N 15/09 (2006.01); **A61K 38/16** (2006.01); **A61K 39/00** (2006.01); **A61K 48/00** (2006.01); **A61P 35/00** (2006.01); **C07K 14/82** (2006.01); **C12N 5/10** (2006.01)

CPC (source: EP)
A61K 38/162 (2013.01); **A61P 35/00** (2018.01); **C07K 14/82** (2013.01); **A61K 39/00** (2013.01); **A61K 48/00** (2013.01); **A61K 2039/51** (2013.01)

Citation (search report)
• [X] WO 9416737 A1 19940804 - WEINER DAVID B [US], et al
• [A] JOHNSON P J ET AL: "OVEREXPRESSED PP60C-SRC CAN INDUCE FOCUS FORMATION WITHOUT COMPLETE TRANSFORMATION OF NIH 3T3 CELLS", MOLECULAR AND CELLULAR BIOLOGY, WASHINGTON, DC, US, vol. 5, no. 5, May 1985 (1985-05-01), pages 1073 - 1083, XP009000334, ISSN: 0270-7306
• [PX] HALPERN MICHAEL S ET AL: "Endogenous c-src as a determinant of the tumorigenicity of src oncogenes.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 93, no. 2, 23 January 1996 (1996-01-23), 1996, pages 824 - 827, XP002228324, ISSN: 0027-8424
• See also references of WO 9725860A1

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9725860 A1 19970724; AU 1699297 A 19970811; AU 717356 B2 20000323; CA 2241952 A1 19970724; EP 0923284 A1 19990623; EP 0923284 A4 20030326; JP 2001501909 A 20010213

DOCDB simple family (application)
US 9700582 W 19970113; AU 1699297 A 19970113; CA 2241952 A 19970113; EP 97902934 A 19970113; JP 52612497 A 19970113